Wimmer Associates 1’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.16M | Sell |
12,574
-210
| -2% | -$45.2K | 1.43% | 15 |
|
|
2026
Q1 | $2.78M | Sell |
12,784
-198
| -2% | -$43.9K | 1.36% | 19 |
|
|
2025
Q4 | $2.97M | Sell |
12,982
-276
| -2% | -$62.9K | 1.38% | 16 |
|
|
2025
Q3 | $3.07M | Sell |
13,258
-250
| -2% | -$50.9K | 1.48% | 16 |
|
|
2025
Q2 | $2.51M | Sell |
13,508
-466
| -3% | -$86.6K | 1.28% | 19 |
|
|
2025
Q1 | $2.63M | Sell |
13,974
-819
| -6% | -$159K | 1.39% | 19 |
|
|
2024
Q4 | $2.63M | Sell |
14,793
-560
| -4% | -$103K | 1.3% | 20 |
|
|
2024
Q3 | $3.03M | Sell |
15,353
-44
| -0.3% | -$8.21K | 1.48% | 17 |
|
|
2024
Q2 | $2.64M | Hold |
15,397
| – | – | 1.35% | 19 |
|
|
2024
Q1 | $2.8M | Sell |
15,397
-1,265
| -8% | -$218K | 1.47% | 19 |
|
|
2023
Q4 | $2.58M | Buy |
16,662
+200
| +1% | +$29.2K | 1.46% | 21 |
|
|
2023
Q3 | $2.45M | Sell |
16,462
-39
| -0.2% | -$5.72K | 1.53% | 20 |
|
|
2023
Q2 | $2.22M | Sell |
16,501
-50
| -0.3% | -$7.33K | 1.34% | 23 |
|
|
2023
Q1 | $2.43M | Sell |
16,551
-426
| -3% | -$65.1K | 1.55% | 21 |
|
|
2022
Q4 | $2.74M | Sell |
16,977
-12
| -0.1% | -$1.84K | 1.81% | 14 |
|
|
2022
Q3 | $2.49M | Sell |
16,989
-107
| -0.6% | -$15.4K | 1.65% | 19 |
|
|
2022
Q2 | $2.62M | Sell |
17,096
-167
| -1% | -$25.5K | 1.71% | 18 |
|
|
2022
Q1 | $2.8M | Buy |
17,263
+400
| +2% | +$58.1K | 1.56% | 20 |
|
|
2021
Q4 | $2.28M | Buy |
16,863
+273
| +2% | +$32.2K | 1.22% | 26 |
|
|
2021
Q3 | $1.79M | Buy |
16,590
+41
| +0.2% | +$4.68K | 1.06% | 30 |
|
|
2021
Q2 | $1.86M | Buy |
16,549
+34
| +0.2% | +$3.83K | 1.09% | 30 |
|
|
2021
Q1 | $1.79M | Sell |
16,515
-192
| -1% | -$20.5K | 0.97% | 31 |
|
|
2020
Q4 | $1.79M | Sell |
16,707
-107
| -0.6% | -$10.3K | 1.07% | 28 |
|
|
2020
Q3 | $1.47M | Buy |
16,814
+947
| +6% | +$89.2K | 0.99% | 31 |
|
|
2020
Q2 | $1.47M | Sell |
15,867
-1,086
| -6% | -$95.6K | 1.14% | 28 |
|
|
2020
Q1 | $1.29M | Buy |
16,953
+1,367
| +9% | +$116K | 1.2% | 29 |
|
|
2019
Q4 | $1.38M | Buy |
15,586
+215
| +1% | +$17.8K | 1.11% | 33 |
|
|
2019
Q3 | $1.16M | Sell |
15,371
-75
| -0.5% | -$5.14K | 1.02% | 37 |
|
|
2019
Q2 | $1.12M | Buy |
15,446
+107
| +0.7% | +$8.41K | 0.98% | 37 |
|
|
2019
Q1 | $1.24M | Sell |
15,339
-120
| -0.8% | -$9.82K | 1.1% | 32 |
|
|
2018
Q4 | $1.43M | Sell |
15,459
-932
| -6% | -$82K | 1.41% | 28 |
|
|
2018
Q3 | $1.55M | Sell |
16,391
-1,925
| -11% | -$183K | 1.29% | 29 |
|
|
2018
Q2 | $1.7M | Buy |
18,316
+59
| +0.3% | +$5.76K | 1.51% | 24 |
|
|
2018
Q1 | $1.73M | Buy |
18,257
+102
| +0.6% | +$11.2K | 1.52% | 25 |
|
|
2017
Q4 | $1.76M | Sell |
18,155
-368
| -2% | -$34.7K | 1.58% | 26 |
|
|
2017
Q3 | $1.65M | Sell |
18,523
-1,097
| -6% | -$83.5K | 1.52% | 26 |
|
|
2017
Q2 | $1.42M | Sell |
19,620
-685
| -3% | -$46.1K | 1.31% | 33 |
|
|
2017
Q1 | $1.32M | Sell |
20,305
-678
| -3% | -$42.6K | 1.24% | 33 |
|
|
2016
Q4 | $1.31M | Sell |
20,983
-457
| -2% | -$27.9K | 1.22% | 31 |
|
|
2016
Q3 | $1.35M | Buy |
21,440
+452
| +2% | +$29.3K | 1.22% | 30 |
|
|
2016
Q2 | $1.3M | Buy |
20,988
+86
| +0.4% | +$5.24K | 1.16% | 31 |
|
|
2016
Q1 | $1.19M | Buy |
20,902
+1,006
| +5% | +$56.1K | 1.09% | 36 |
|
|
2015
Q4 | $1.18M | Buy |
+19,896
| New | +$1.15M | 1.24% | 31 |
|
Other funds holding ABBV
Wimmer Associates 1's ABBV Position: Q2 2026 in Review
Wimmer Associates 1 reduced its AbbVie (ABBV) stake by 1.6% in Q2 2026, selling an estimated $45.2K and leaving 12,574 shares worth $3.16M. The position accounts for 1.43% of the portfolio, ranked #15.
Wimmer Associates 1 first reported a position in ABBV in Q4 2015 and has held it in 43 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Wimmer Associates 1 held 12,574 shares of AbbVie worth $3.16M as of Q2 2026.
- Wimmer Associates 1 sold 210 AbbVie shares in Q2 2026, an estimated $45.2K.
- AbbVie made up 1.43% of Wimmer Associates 1's portfolio in Q2 2026, its #15 holding.
- Wimmer Associates 1 first reported a position in AbbVie in Q4 2015 and has held it in 43 quarters since.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Wimmer Associates 1's 13F filing for Q2 2026, filed 14 Aug 2026.